Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Board of Directors of Bellerophon Therapeutics, Inc. (the "Company")
appointed Peter Fernandes, the Company's current Chief Executive Officer and
Chief Regulatory & Safety Officer, as the Company's Principal Financial and
Accounting Officer effective as of May 5, 2023, until his successor is
appointed. No family relationships exist between Mr. Fernandes and any of our
directors or executive officers. There are no arrangements or understandings
between Mr. Fernandes and any other person pursuant to which he was selected as
the Principal Financial and Accounting Officer. Mr. Fernandes will not receive
any additional compensation as Principal Financial and Accounting Officer. Mr.
Fernandes does not have a direct or indirect material interest in any
transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Peter Fernandes has served as our Chief Executive Officer since December 2022
having previously served as our Principal Executive Officer since November 2021
and as our Chief Regulatory, Safety & Quality Officer since May 2015. Prior to
joining us, Mr. Fernandes was Vice President of Global Regulatory Affairs at
Ikaria Inc., from October 2012 to May 2015, and in this capacity also led our
regulatory group since its inception in February 2014. Previously, he led
Regulatory Affairs and Quality Assurance for OptiNose, Inc. from October 2010 to
September 2012, was Vice President US Drug Regulatory Affairs Respiratory and US
DRA Respiratory Franchise Head for Novartis Pharmaceuticals from November 2007
to October 2010. He has also served as the Head of US Development Site and Vice
President of Regulatory Affairs and Quality Assurance at Altana Pharma, a
subsidiary of Nycomed Inc., and led the US Respiratory and GI Drug Regulatory
Affairs group at Boehringer Ingelheim. Mr. Fernandes has over 30 years of
experience leading cross functional global development teams covering
respiratory and cardiovascular diseases with successful US and global
submissions and approvals obtained for a number of well-known drugs e.g.,
Flomax, Spiriva, Omnaris. Mr. Fernandes also serves as Co-Chair of the Pulmonary
Vascular Research Institute (PVRI) Innovative Drug Development Initiative that
is instrumental in developing novel regulatory endpoints and clinical trial
design for Pulmonary Hypertension (PH) in collaboration with academia, industry
and regulators. Mr. Fernandes has an M. Pharm. from the Grant Medical College
and a B. Pharm. from the K.M. K College of Pharmacy, both at the University of
Bombay in India.
2
© Edgar Online, source Glimpses